Registration Number
0220U102648,
0117U000407
, R & D reports
Title
To optimize treatment in patients with metastatic breast cancer molecular subtypes adverse prognostic
popup.stage_title
Head
Syvak Lubov А., Доктор медичних наук
Registration Date
22-04-2020
Organization
National Cancer Institute
popup.description2
Object of the study - 152 patients with metastatic breast cancer, 65 patients with luminal In breast cancer and 87 - with three times negative breast cancer. The purpose of the work is to increase the effectiveness of treatment of patients with metastatic three times negative and luminal B subtypes of breast cancer by applying the most effective modes of chemotherapy based on the study of morphological and immunohistochemical factors of prognosis and their impact on the course of the disease. When studying the features of lymphoid infiltration of tumor tissue in patients with three times negative breast cancer, it was found that a high level of peritumoral CD4 + lymphocytes at the time of diagnosis raises the risk of metastasis in patients with three times negative breast cancer 1,73 ; 95% CI 1.27–2.37; p <0.001), however, a high FOXP3 + lymphocyte level in the immune infiltrate at the time of diagnosis indicates a decrease in the likelihood of recurrence (HR 0.66; 95% CI 0.50–0, 88; p = 0.005) in patients with three times negative breast cancer Noah's gland. It was found that the risk of death from breast cancer was different in patients with different ratios of CD8 + lymphocytes and FOXP3 + lymphocytes. In patients with metastatic breast cancer, the prognosis of unfavorable molecular subtypes of the ratio of circulating lymphocytes expressing activation markers CD95 and HLA-DR is consistent with that in PCG. Instead, patients with luminal In Her2 / neu negative RGS have a decrease in the relative number of CD25 + cells among peripheral blood lymphocytes. Reduced expression of ITSN2 mRNA in tumors with unfavorable diagonosis (ER +/– PR +/– HER2 / neu +). Decreased expression was observed in the total number of ITSN2 isoforms and separately short isoforms (ITSN2-S). This indicates the possibility of using ITSN2-S as a prognostic marker of breast cancer. No significant differences in the expression of ITSN2-L and TKS5-L in the analyzed samples were found.
Product Description
popup.authors
Askolskyy Anton V
Verʹovkina Natalya O
Dasiukevich Olga Yo
Kukushkina Svitlana M
Lyalkin Sergiy A
Martynyuk Olena M
Orel Valeriy E
Rykhalskyy Oleksandr Yu
Tarasenko Tetyana Ye
Filchakov Feodosiy V
Shepel Oleksandr V
Yatsenko Lyudmyla D
popup.nrat_date
2020-07-03
